SALT LAKE CITY, April 06, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancerous esophageal diseases, today announced it will be giving a data presentation this week at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8 – 13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
The presentation will be given by Christopher P. Hartley, MD of the Mayo Clinic, a board certified pathologist, and principal investigator of Stella Diagnostics’ Collaborative Research Agreement with the Mayo Clinic to assess the performance of the Company's STLA101 panel that detects and quantifies hallmarks of cancer development in tissue of patients diagnosed with Barrett's esophagus, a precancerous condition with high incidence in the U.S. Director of Norton Thoracic Institute, Dr. Sumeet Mittal, Dr. Ajay Bansal of Kansas University Medical Center and Dr. Joe Abdo, CEO of Stella Diagnostics serve as co-authors of the abstract.
Details of the presentation are as follows:
Title: “Mass spectrometry detects lower frequency of routine markers and consistent overexpression of novel disease drivers in Barrett's-related esophageal cancer”
Session Category: Clinical Research
Session Title: Diagnostic Biomarkers
Session Date and Time: Tuesday Apr 12, 2022, 9:00 AM - 12:30 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Section 32
Abstract Number: 2805
The AACR has more than 49,000 members residing in 128 countries. Members include laboratory, translational, and clinical researchers; other health care professionals; and cancer advocates. Membership includes 256 Fellows of the AACR Academy; 54 are Nobel laureates.
Dr. Joe Abdo, CEO of Stella Diagnostics, said, “We are very excited to be sharing our data at the AACR annual meeting, which is one of my favorite conferences of the year because of the hyper-focus of clinical research in the advancement of medical oncology. The AACR annual meeting is a great opportunity to introduce the science behind our early cancer detection assay and observe novel advances that have been made in the global oncology community. We look forward to showcasing the clinical advantages of our diagnostic assay that illuminate the carcinogenic proteomic milieu that leads to an increase in cellular proliferation, invasion, migration, metastasis, and cell survival as well as chemotherapeutic resistance to the most commonly prescribed drugs for esophageal adenocarcinoma.”
Esophageal adenocarcinoma is the fastest rising cancer in the United States, with a 700% increase in incidence over the last four decades (Thuy-Van P. Hang, et al). The majority of these patients are diagnosed with gastroesophageal reflux disease (GERD) and Barrett's esophagus before their cancer is detected. Even though Barrett’s patients are screened routinely for disease progression, 4 out of 5 esophageal cancer patients still present to their oncologist in the advanced stages when the disease is uncurable.
About Stella Diagnostics
Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 60 million people living with severe esophageal disease. Stella Diagnostics’ clinical assay will offer physicians insight into the molecular properties of their patients' tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives. For more information, please visit www.stelladx.com.
Forward Looking Statements
Certain statements made in this press release are "forward looking statements" that are based on Stella Diagnostics' beliefs, assumptions, current expectations, estimates and projections. Forward looking statements involve known and unknown risks and uncertainties that may cause forecasted results to differ from actual results. Such risks include, but are not limited to market conditions, competitive factors, the ability to complete the proposed transaction and other such related risks. Stella Diagnostics can give no assurances that any projections related to revenues, profit margins or profits will be realized. Statements that are not historical fact, including without limitation statements which are preceded by, followed by or include the words "believes," "anticipates," "plans," "expects," "estimates," "may," "should," "intends," or similar expressions are forward looking statements. While Stella Diagnostics believes these assumptions, expectations, estimates, and projections are reasonable, such statements are subject to risks and uncertainties, certain of which are beyond our control and therefore, actual results may differ materially. Stella Diagnostics believes that many of the risks detailed here are part of doing business in the industry in which we would operate and compete. Forward looking statements only speak as of the date hereof and we do not undertake and expressly disclaim any obligation to update or release any revisions to any forward-looking statement whether as a result of new information, future events or otherwise except as required by law. While we believe the information used in this press release to be reliable, its accuracy has not been independently verified and cannot be guaranteed. Stella Diagnostics can give no assurances that any projections related to revenues, profit margins or profits will be realized.
Investors and Media Contact:
David L. Kugelman
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: info@stelladx.com
Skype: kugsusa
LinkedIn: https://www.linkedin.com/in/davidkugelman
